FXView Broker Review: Regulated but Is It Safe for Traders?
Abstract:This FXVIEW review provides a detailed examination of the regulatory standing, licensing framework, and WikiScore rating for the FXVIEW broker based on information available on WikiFX.

This FXVIEW review provides a detailed examination of the broker regulatory standing, licensing framework, and WikiScore rating based on information available on WikiFX. As a global broker regulatory query platform, WikiFX evaluates brokers using criteria such as regulatory authorisation, operational transparency, and compliance records.
According to WikiFX, the FXVIEW broker holds a WikiScore of 5.99 out of 10, placing it within a moderate range among global brokers. This rating reflects a combination of its regulatory coverage and operational indicators, but also takes into account a number of concerns that traders evaluating the broker FXVIEW should be aware of before making a decision.

View the full WikiFX profile for review FXVIEW research here: https://www.wikifx.com/en/dealer/1080904101.html
Overview of FXVIEW Broker
FXVIEW is operated by Finvasia Capital South Africa (PTY) LTD and has been in operation for between five and ten years. The FXVIEW broker offers trading on forex, commodities, cryptocurrencies, indices, and stocks, with leverage of up to 1:1000 and spreads from 0.0 pips on its ECN account types. The minimum deposit for the RAW ECN account stands at 50 USD, while the Premium ECN account requires a minimum of 5,000 USD. Supported trading platforms include MT5, ActTrader, and the proprietary Fxview application.
Regulatory Framework for FXVIEW Regulation and Licences
Understanding FXVIEW regulation across each licensing authority is essential for evaluating safety and trader protections.
Cyprus Securities and Exchange Commission (CySEC)
FXVIEW holds a Derivatives Trading Licence issued by CySEC with licence number 367/18, under the registered entity Charlgate Ltd. CySEC is the national financial regulator of Cyprus and operates within the European Union regulatory framework.
Firms regulated under CySEC FXVIEW regulation policies are required to comply with European directives governing financial services, including requirements related to capital adequacy, segregation of client funds, and regular financial reporting. The Straight Through Processing model associated with this licence indicates that client orders are typically routed to external liquidity providers, which may reduce conflicts of interest in trade execution.
Financial Sector Conduct Authority of South Africa (FSCA)
In addition to its European licence, FXVIEW is associated with a Derivatives Trading Licence from the FSCA under licence number 50410. However, WikiFX has flagged this FSCA licence as a suspicious clone, which raises questions about the authenticity and scope of the regulatory coverage it provides for the broker FXVIEW in the South African market.
The FSCA is responsible for regulating financial service providers in South Africa, focusing on fair customer treatment and market integrity. While a legitimate FSCA licence represents meaningful oversight, traders reviewing regulation FXVIEW details should note the classification of this particular licence by WikiFX with caution.
Conclusion: Final Review FXVIEW Verdict
This FXVIEW review outlines a broker with a WikiScore of 5.99 out of 10 and a regulatory profile that warrants careful consideration. While the active CySEC licence provides a degree of recognised European oversight, the revoked FCA licence and the suspicious clone classification of the FSCA licence introduce meaningful uncertainties under FXVIEW regulation standards.
Traders considering the broker FXVIEW are advised to verify which entity governs their account and assess the regulatory protections available to them accordingly before proceeding.

Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.










